[go: up one dir, main page]

MX2023008370A - Composicion farmaceutica orodispersable de clonazepam - Google Patents

Composicion farmaceutica orodispersable de clonazepam

Info

Publication number
MX2023008370A
MX2023008370A MX2023008370A MX2023008370A MX2023008370A MX 2023008370 A MX2023008370 A MX 2023008370A MX 2023008370 A MX2023008370 A MX 2023008370A MX 2023008370 A MX2023008370 A MX 2023008370A MX 2023008370 A MX2023008370 A MX 2023008370A
Authority
MX
Mexico
Prior art keywords
clonazepam
treatment
solid oral
pharmaceutical composition
present
Prior art date
Application number
MX2023008370A
Other languages
English (en)
Inventor
Rojas Marisol Alarid
Gallardo Rodrigo Alejandro Hernandez
Vargas Miriam Villa
Hernandez Omar Crespo
Original Assignee
Posi Visionary Solutions Llp
Productos Cientificos S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Posi Visionary Solutions Llp, Productos Cientificos S A De C V filed Critical Posi Visionary Solutions Llp
Priority to MX2023008370A priority Critical patent/MX2023008370A/es
Priority to CL2023002058A priority patent/CL2023002058A1/es
Priority to PE2024000345A priority patent/PE20250418A1/es
Priority to CONC2024/0002677A priority patent/CO2024002677A1/es
Priority to UY0001040818A priority patent/UY40818A/es
Priority to ARP240101807A priority patent/AR133232A1/es
Priority to PCT/IB2024/056816 priority patent/WO2025012877A1/es
Publication of MX2023008370A publication Critical patent/MX2023008370A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q90/00—Cosmetics or similar toiletry preparations for specific uses not provided for in other groups of this subclass

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención refiere a nuevas composiciones sólidas de desintegración oral que presentan un perfil de liberación de clonazepam sustancialmente similar o igual al que presenta una composición líquida de clonazepam de liberación inmediata, que además presenta una rápida desintegración, baja friabilidad y propiedades organolépticas agradables para el paciente. Además, las nuevas composiciones sólidas de desintegración oral de la presente invención son útiles para el tratamiento de trastornos neurológicos que incluyen el tratamiento de epilepsia tanto crónica generalizada (ausencias, pequeño mal) como crónica parcial (crisis focales y complejas).
MX2023008370A 2023-07-13 2023-07-13 Composicion farmaceutica orodispersable de clonazepam MX2023008370A (es)

Priority Applications (7)

Application Number Priority Date Filing Date Title
MX2023008370A MX2023008370A (es) 2023-07-13 2023-07-13 Composicion farmaceutica orodispersable de clonazepam
CL2023002058A CL2023002058A1 (es) 2023-07-13 2023-07-14 Composición farmacéutica orodispersable de clonazepam.
PE2024000345A PE20250418A1 (es) 2023-07-13 2024-02-29 Composicion farmaceutica orodispersable de clonazepam
CONC2024/0002677A CO2024002677A1 (es) 2023-07-13 2024-03-01 Composición farmacéutica orodispersable de clonazepam
UY0001040818A UY40818A (es) 2023-07-13 2024-07-11 Composición farmacéutica orodispersable de clonazepam
ARP240101807A AR133232A1 (es) 2023-07-13 2024-07-12 Composición farmacéutica orodispersable de clonazepam
PCT/IB2024/056816 WO2025012877A1 (es) 2023-07-13 2024-07-12 Composición farmacéutica orodispersable de clonazepam

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2023008370A MX2023008370A (es) 2023-07-13 2023-07-13 Composicion farmaceutica orodispersable de clonazepam

Publications (1)

Publication Number Publication Date
MX2023008370A true MX2023008370A (es) 2025-02-10

Family

ID=89507668

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008370A MX2023008370A (es) 2023-07-13 2023-07-13 Composicion farmaceutica orodispersable de clonazepam

Country Status (7)

Country Link
AR (1) AR133232A1 (es)
CL (1) CL2023002058A1 (es)
CO (1) CO2024002677A1 (es)
MX (1) MX2023008370A (es)
PE (1) PE20250418A1 (es)
UY (1) UY40818A (es)
WO (1) WO2025012877A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible
US20070196494A1 (en) * 2006-02-17 2007-08-23 Arnaud Grenier Low-friability, patient-friendly orally disintegrating formulations
JP5535616B2 (ja) * 2006-03-31 2014-07-02 ルビコン リサーチ プライベート リミテッド 口腔内崩壊錠剤のための直接圧縮性複合材

Also Published As

Publication number Publication date
WO2025012877A1 (es) 2025-01-16
PE20250418A1 (es) 2025-02-14
CO2024002677A1 (es) 2024-05-30
UY40818A (es) 2024-08-30
AR133232A1 (es) 2025-09-10
CL2023002058A1 (es) 2023-12-29

Similar Documents

Publication Publication Date Title
MX2024000208A (es) Restos de administracion terapeutica novedosos y usos de estos.
EA200970287A1 (ru) Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты
TW200716546A (en) Oxindole compounds and their uses as therapeutic agents
MY140576A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
PL371428A1 (en) Substituted indolizine-like compounds and methods of use
MA31822B1 (fr) Compositions et methodes d'utilisation de peptides pro-ilot et leur analogues
ATE454140T1 (de) Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
SG146648A1 (en) Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
SG145693A1 (en) Amino acid prodrugs
NZ591810A (en) Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
CL2004000437A1 (es) Compuestos heterociclicos del tipo [1,4]-diazepan-2-ona sustituidos, inhibidores de la enzima dipeptidilpeptidasa-iv (cdp-iv); composicion farmaceutica; y su uso para preparar un medicamento para tratar hiperglucemia, diabetes tipo 2, obesidad, trast
TW200727918A (en) Pharmaceutical preparation containing meloxicam
IL183236A0 (en) Rasagiline orally disintegrating compositions
WO2008002621A3 (en) Benzyl-substituted quinolone m1 receptor positive allosteric modulators
WO2004043341A3 (en) Treatment for hemorrhagic shock
WO2022173888A8 (en) Pharmaceutically acceptable salts of psilocin and uses thereof
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
MX2024014216A (es) Compuestos aromaticos que contienen boro y analogos de insulina relacionados
MX2023008370A (es) Composicion farmaceutica orodispersable de clonazepam
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
MX2022007175A (es) Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.
MA33804B1 (fr) Composition pharmaceutique pour le traitement des brûlures cutanées
HUP0401940A2 (hu) Diabetikus neuropátia esetében alkalmazható gyógyszerkészítmény
MA30489B1 (fr) Compositions nasale et buccale pour lutter contre le ronflement
HU0002154D0 (en) Pharmaceutical compositions for treatment depression or symptoms concerning to depression